-
Product Insights
NewSerine/Threonine Protein Kinase Pim – Drugs In Development, 2024
The Serine/Threonine Protein Kinase Pim pipeline drugs market research report outlays comprehensive information on the Serine/Threonine Protein Kinase Pim targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, Gastrointestinal, and Infectious Disease which include indications of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Oncology, Psoriasis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, and...
-
Product Insights
NewSerine/Threonine Protein Kinase Pim 3 – Drugs In Development, 2024
The Serine/Threonine Protein Kinase Pim 3 pipeline drugs market research report outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, and Gastrointestinal which include indications of Hematological Tumor, Chronic Lymphocytic Leukemia (CLL), Psoriasis, Rheumatoid Arthritis, and Inflammatory Bowel Disease. It also reviews key players involved in...
-
Product Insights
NewSerine/Threonine Protein Kinase Pim 2 – Drugs In Development, 2024
The Serine/Threonine Protein Kinase Pim 2 pipeline drugs market research report outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, and Gastrointestinal which include indications of Hematological Tumor, Oncology, Psoriasis, Rheumatoid Arthritis, and Inflammatory Bowel Disease. It also reviews key players involved in Serine/Threonine Protein Kinase...
-
Product Insights
NewSerine/Threonine Protein Kinase Pim 1 – Drugs In Development, 2024
The Serine/Threonine Protein Kinase Pim 1 pipeline drugs market research report outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, Gastrointestinal, and Respiratory which include indications of Hematological Tumor, Oncology, Psoriasis, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Asthma. It also reviews key players involved in Serine/Threonine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MEN-1703 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MEN-1703 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MEN-1703 in Relapsed Acute Myeloid Leukemia Drug Details: MEN-1703...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MEN-1703 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MEN-1703 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MEN-1703 in Refractory Acute Myeloid Leukemia Drug Details: MEN-1703...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MEN-1703 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MEN-1703 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MEN-1703 in Acute Myelocytic Leukemia (AML,...
-
Product Insights
NewQuarterly Cookies (Sweet Biscuits) pricing trends in France
Empower your strategies with our Quarterly Cookies (Sweet Biscuits) pricing trends in France report and make more profitable business decisions. Consumers’ preferences for stores are most heavily influenced by pricing and promotions, but brands and retailers continue to adjust prices and promotions based on insufficient information from expensive, drawn-out, and incomplete audits of rival techniques. Brands and retailers can benefit from the unique intelligence provided by GlobalData Ecommerce Price Tracker, covering millions of SKUs, to identify, anticipate, and implement important...
-
Product Insights
NewQuarterly Cookies (Sweet Biscuits) pricing trends in Spain
Empower your strategies with our Quarterly Cookies (Sweet Biscuits) pricing trends in Spain report and make more profitable business decisions. Consumers’ preferences for stores are most heavily influenced by pricing and promotions, but brands and retailers continue to adjust prices and promotions based on insufficient information from expensive, drawn-out, and incomplete audits of rival techniques. Brands and retailers can benefit from the unique intelligence provided by GlobalData Ecommerce Price Tracker, covering millions of SKUs, to identify, anticipate, and implement important...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TP-3654 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TP-3654 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TP-3654 in Triple-Negative Breast Cancer (TNBC) Drug Details: TP-3654 (SGI-9481)...